Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.50
-0.0100-0.66%
Post-market: 1.510.0100+0.67%19:59 EDT
Volume:462.37K
Turnover:692.12K
Market Cap:127.45M
PE:-2.25
High:1.53
Open:1.52
Low:1.48
Close:1.51
52wk High:2.75
52wk Low:0.6254
Shares:84.96M
Float Shares:83.54M
Volume Ratio:0.71
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6674
EPS(LYR):-0.6674
ROE:-307.27%
ROA:-41.29%
PB:-20.81
PE(LYR):-2.25

Loading ...

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Investing.com
·
Apr 02

Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 02

BUZZ-Milestone Pharma falls after TD Cowen downgrades to "hold", removes PT

Reuters
·
Apr 01

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating

MT Newswires Live
·
Apr 01

TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy

MT Newswires Live
·
Apr 01

BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed

Reuters
·
Mar 29

Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 29

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher

Benzinga
·
Mar 29

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating

MT Newswires Live
·
Mar 28

BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT

Reuters
·
Mar 28

BUZZ-Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray

Reuters
·
Mar 28

FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray

Dow Jones
·
Mar 28

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Reuters
·
Mar 28

FDA Issues Complete Response Letter for Etripamil for PSVT

GlobeNewswire
·
Mar 28

Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 17

Milestone Pharmaceuticals’ SEC Exemptions: Balancing Reduced Disclosure with Investor Confidence Risks

TIPRANKS
·
Mar 14

Milestone Pharmaceuticals: Q4 Earnings Snapshot

Associated Press Finance
·
Mar 13

Milestone Pharmaceuticals FY 2024 GAAP EPS $(0.67) Misses $(0.62) Estimate, Cash Balance Of $69.7M

Benzinga
·
Mar 13

Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Dow Jones
·
Mar 13

Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule

TIPRANKS
·
Mar 04